COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership. Levander, X. A., Pytell, J. D., Stoller, K. B., Korthuis, P. T., & Chander, G. Subst Abus, 43(1):633–639, 2022. Edition: 20211019![COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex Background: In the United States, methadone for treatment of opioid use disorder is dispensed via highly-regulated accredited opioid treatment programs (OTP). During the COVID-19 pandemic, federal regulations were loosened, allowing for greater use of take-home methadone doses. We sought to understand how OTP leaders responded to these policy changes. Methods: We distributed a multistate electronic survey from September to November 2020 of OTP leadership to members of the American Association for the Treatment of Opioid Dependence (AATOD) who self-identified as leaders of OTPs. We asked study participants about how their OTP(s) implemented COVID-19-related policy changes into their clinical practice focusing on provision of take-home methadone doses, factors used to determine patient stability, and potential concerns about increased take-home doses. We used Chi-square test to compare survey responses between characterizations of the OTPs. Results: Of 170 survey respondents (17% response rate), the majority represented leadership of for-profit OTPs (69%) and were in a Southern state (54%). Routine allowances and practices related to take-home methadone doses varied across OTPs during the COVID-19 pandemic: 80 (47%) reported 14 days for newly enrolled patients (within past 90 days), 89 (52%) reported 14 days for "less stable" patients, and 112 (66%) reported 28 days for "stable" patients. Conclusions: We found that not all eligible OTP leaders adopted the practice of routinely allowing newly enrolled, "less stable," and "stable" patients on methadone to have increased take-home doses up to the limit allowed by federal regulations during COVID-19. The pandemic provides an opportunity to critically re-evaluate long-established methadone and OTP regulations in preparation for future emergencies.
@article{levander_covid-19-related_2022,
title = {{COVID}-19-related policy changes for methadone take-home dosing: {A} multistate survey of opioid treatment program leadership},
volume = {43},
issn = {1547-0164 (Electronic) 0889-7077 (Linking)},
url = {https://www.ncbi.nlm.nih.gov/pubmed/34666636},
doi = {10.1080/08897077.2021.1986768},
abstract = {Background: In the United States, methadone for treatment of opioid use disorder is dispensed via highly-regulated accredited opioid treatment programs (OTP). During the COVID-19 pandemic, federal regulations were loosened, allowing for greater use of take-home methadone doses. We sought to understand how OTP leaders responded to these policy changes. Methods: We distributed a multistate electronic survey from September to November 2020 of OTP leadership to members of the American Association for the Treatment of Opioid Dependence (AATOD) who self-identified as leaders of OTPs. We asked study participants about how their OTP(s) implemented COVID-19-related policy changes into their clinical practice focusing on provision of take-home methadone doses, factors used to determine patient stability, and potential concerns about increased take-home doses. We used Chi-square test to compare survey responses between characterizations of the OTPs. Results: Of 170 survey respondents (17\% response rate), the majority represented leadership of for-profit OTPs (69\%) and were in a Southern state (54\%). Routine allowances and practices related to take-home methadone doses varied across OTPs during the COVID-19 pandemic: 80 (47\%) reported 14 days for newly enrolled patients (within past 90 days), 89 (52\%) reported 14 days for "less stable" patients, and 112 (66\%) reported 28 days for "stable" patients. Conclusions: We found that not all eligible OTP leaders adopted the practice of routinely allowing newly enrolled, "less stable," and "stable" patients on methadone to have increased take-home doses up to the limit allowed by federal regulations during COVID-19. The pandemic provides an opportunity to critically re-evaluate long-established methadone and OTP regulations in preparation for future emergencies.},
number = {1},
journal = {Subst Abus},
author = {Levander, X. A. and Pytell, J. D. and Stoller, K. B. and Korthuis, P. T. and Chander, G.},
year = {2022},
note = {Edition: 20211019},
keywords = {*Methadone, *Opioid-Related Disorders/drug therapy, *covid-19, *opioid treatment programs, *opioid-related disorders, *survey, Analgesics, Opioid/therapeutic use, Covid-19, Humans, Leadership, Methadone, Methadone/therapeutic use, Opiate Substitution Treatment, Pandemics, Policy, SARS-CoV-2, Surveys and Questionnaires, United States, opioid treatment programs, opioid-related disorders, survey},
pages = {633--639},
}
Downloads: 0
{"_id":"n7rPcvh4aKPEAvD6W","bibbaseid":"levander-pytell-stoller-korthuis-chander-covid19relatedpolicychangesformethadonetakehomedosingamultistatesurveyofopioidtreatmentprogramleadership-2022","author_short":["Levander, X. A.","Pytell, J. D.","Stoller, K. B.","Korthuis, P. T.","Chander, G."],"bibdata":{"bibtype":"article","type":"article","title":"COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership","volume":"43","issn":"1547-0164 (Electronic) 0889-7077 (Linking)","url":"https://www.ncbi.nlm.nih.gov/pubmed/34666636","doi":"10.1080/08897077.2021.1986768","abstract":"Background: In the United States, methadone for treatment of opioid use disorder is dispensed via highly-regulated accredited opioid treatment programs (OTP). During the COVID-19 pandemic, federal regulations were loosened, allowing for greater use of take-home methadone doses. We sought to understand how OTP leaders responded to these policy changes. Methods: We distributed a multistate electronic survey from September to November 2020 of OTP leadership to members of the American Association for the Treatment of Opioid Dependence (AATOD) who self-identified as leaders of OTPs. We asked study participants about how their OTP(s) implemented COVID-19-related policy changes into their clinical practice focusing on provision of take-home methadone doses, factors used to determine patient stability, and potential concerns about increased take-home doses. We used Chi-square test to compare survey responses between characterizations of the OTPs. Results: Of 170 survey respondents (17% response rate), the majority represented leadership of for-profit OTPs (69%) and were in a Southern state (54%). Routine allowances and practices related to take-home methadone doses varied across OTPs during the COVID-19 pandemic: 80 (47%) reported 14 days for newly enrolled patients (within past 90 days), 89 (52%) reported 14 days for \"less stable\" patients, and 112 (66%) reported 28 days for \"stable\" patients. Conclusions: We found that not all eligible OTP leaders adopted the practice of routinely allowing newly enrolled, \"less stable,\" and \"stable\" patients on methadone to have increased take-home doses up to the limit allowed by federal regulations during COVID-19. The pandemic provides an opportunity to critically re-evaluate long-established methadone and OTP regulations in preparation for future emergencies.","number":"1","journal":"Subst Abus","author":[{"propositions":[],"lastnames":["Levander"],"firstnames":["X.","A."],"suffixes":[]},{"propositions":[],"lastnames":["Pytell"],"firstnames":["J.","D."],"suffixes":[]},{"propositions":[],"lastnames":["Stoller"],"firstnames":["K.","B."],"suffixes":[]},{"propositions":[],"lastnames":["Korthuis"],"firstnames":["P.","T."],"suffixes":[]},{"propositions":[],"lastnames":["Chander"],"firstnames":["G."],"suffixes":[]}],"year":"2022","note":"Edition: 20211019","keywords":"*Methadone, *Opioid-Related Disorders/drug therapy, *covid-19, *opioid treatment programs, *opioid-related disorders, *survey, Analgesics, Opioid/therapeutic use, Covid-19, Humans, Leadership, Methadone, Methadone/therapeutic use, Opiate Substitution Treatment, Pandemics, Policy, SARS-CoV-2, Surveys and Questionnaires, United States, opioid treatment programs, opioid-related disorders, survey","pages":"633–639","bibtex":"@article{levander_covid-19-related_2022,\n\ttitle = {{COVID}-19-related policy changes for methadone take-home dosing: {A} multistate survey of opioid treatment program leadership},\n\tvolume = {43},\n\tissn = {1547-0164 (Electronic) 0889-7077 (Linking)},\n\turl = {https://www.ncbi.nlm.nih.gov/pubmed/34666636},\n\tdoi = {10.1080/08897077.2021.1986768},\n\tabstract = {Background: In the United States, methadone for treatment of opioid use disorder is dispensed via highly-regulated accredited opioid treatment programs (OTP). During the COVID-19 pandemic, federal regulations were loosened, allowing for greater use of take-home methadone doses. We sought to understand how OTP leaders responded to these policy changes. Methods: We distributed a multistate electronic survey from September to November 2020 of OTP leadership to members of the American Association for the Treatment of Opioid Dependence (AATOD) who self-identified as leaders of OTPs. We asked study participants about how their OTP(s) implemented COVID-19-related policy changes into their clinical practice focusing on provision of take-home methadone doses, factors used to determine patient stability, and potential concerns about increased take-home doses. We used Chi-square test to compare survey responses between characterizations of the OTPs. Results: Of 170 survey respondents (17\\% response rate), the majority represented leadership of for-profit OTPs (69\\%) and were in a Southern state (54\\%). Routine allowances and practices related to take-home methadone doses varied across OTPs during the COVID-19 pandemic: 80 (47\\%) reported 14 days for newly enrolled patients (within past 90 days), 89 (52\\%) reported 14 days for \"less stable\" patients, and 112 (66\\%) reported 28 days for \"stable\" patients. Conclusions: We found that not all eligible OTP leaders adopted the practice of routinely allowing newly enrolled, \"less stable,\" and \"stable\" patients on methadone to have increased take-home doses up to the limit allowed by federal regulations during COVID-19. The pandemic provides an opportunity to critically re-evaluate long-established methadone and OTP regulations in preparation for future emergencies.},\n\tnumber = {1},\n\tjournal = {Subst Abus},\n\tauthor = {Levander, X. A. and Pytell, J. D. and Stoller, K. B. and Korthuis, P. T. and Chander, G.},\n\tyear = {2022},\n\tnote = {Edition: 20211019},\n\tkeywords = {*Methadone, *Opioid-Related Disorders/drug therapy, *covid-19, *opioid treatment programs, *opioid-related disorders, *survey, Analgesics, Opioid/therapeutic use, Covid-19, Humans, Leadership, Methadone, Methadone/therapeutic use, Opiate Substitution Treatment, Pandemics, Policy, SARS-CoV-2, Surveys and Questionnaires, United States, opioid treatment programs, opioid-related disorders, survey},\n\tpages = {633--639},\n}\n\n\n\n\n\n\n\n","author_short":["Levander, X. A.","Pytell, J. D.","Stoller, K. B.","Korthuis, P. T.","Chander, G."],"key":"levander_covid-19-related_2022","id":"levander_covid-19-related_2022","bibbaseid":"levander-pytell-stoller-korthuis-chander-covid19relatedpolicychangesformethadonetakehomedosingamultistatesurveyofopioidtreatmentprogramleadership-2022","role":"author","urls":{"Paper":"https://www.ncbi.nlm.nih.gov/pubmed/34666636"},"keyword":["*Methadone","*Opioid-Related Disorders/drug therapy","*covid-19","*opioid treatment programs","*opioid-related disorders","*survey","Analgesics","Opioid/therapeutic use","Covid-19","Humans","Leadership","Methadone","Methadone/therapeutic use","Opiate Substitution Treatment","Pandemics","Policy","SARS-CoV-2","Surveys and Questionnaires","United States","opioid treatment programs","opioid-related disorders","survey"],"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero-group/Sierramatice/2808357","dataSources":["3wdaKc5dBzq6bPRq5"],"keywords":["*methadone","*opioid-related disorders/drug therapy","*covid-19","*opioid treatment programs","*opioid-related disorders","*survey","analgesics","opioid/therapeutic use","covid-19","humans","leadership","methadone","methadone/therapeutic use","opiate substitution treatment","pandemics","policy","sars-cov-2","surveys and questionnaires","united states","opioid treatment programs","opioid-related disorders","survey"],"search_terms":["covid","related","policy","changes","methadone","take","home","dosing","multistate","survey","opioid","treatment","program","leadership","levander","pytell","stoller","korthuis","chander"],"title":"COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership","year":2022}